Methods and systems for converting precursor cells into intestinal tissues through directed differentiation

Patent metadata

Field	Value
Publication number	US-9719068-B2
Application number	US-201113695887-A
Country	US
Kind code	B2
Filing date	May 6, 2011
Priority date	May 6, 2010
Publication date	Aug 1, 2017
Grant date	Aug 1, 2017

Abstract

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

First claim

What is claimed is:

1. An in vitro method of inducing formation of mammalian intestinal tissue, comprising the steps of:
a) contacting mammalian definitive endoderm cells with 100 ng/ml of FGF4 or higher and 100 ng/ml or higher Wnt3a for at least 96 hours to obtain posterior definitive endoderm cells,
b) culturing the posterior definitive endoderm cells of step (a) to obtain 3-dimensional spheroids,
c) embedding the 3-dimensional spheroids of step (b) in a basement membrane-like matrix to obtain intestinal tissue; and
d) maintaining said embedded intestinal tissue in a media comprising at least 50 ng/mL of EGF, wherein said maintaining produces a stable mammalian intestinal tissue.

2. The method of claim 1 , wherein said definitive endoderm cell is contacted by Wnt3a during a first activation period and by FGF4 during a second activation period.

3. The method of claim 2 , wherein said first activation period and said second activation period overlap.

4. The method of claim 2 , wherein said first activation period and said second activation period do not overlap.

5. The method of claim 1 , wherein the definitive endoderm cell is derived from a mouse or human pluripotent stem cell.

6. The method of claim 5 , wherein said pluripotent stem cell is an embryonic stem cell or an induced pluripotent stem cell.

7. The method of claim 5 , wherein said definitive endoderm cell is derived by contacting the pluripotent stem cell with one or more molecules selected from the group consisting of Activin, the BMP subgroups of the TGF-β superfamily of growth factors; Nodal, Activin A, Activin B, BMP4, Wnt3a, and combinations thereof.

8. The method of claim 5 , wherein said pluripotent stem cell is a human pluripotent stem cell.

9. The method of claim 8 , wherein said human pluripotent stem cell is selected from the group consisting of a human embryonic stem cell, a human embryonic germ cell, and an induced human pluripotent stem cell.

Assignees

• Wells James M
• Spence Jason R
• Zorn Aaron M
• Shroyer Noah F
• Children'S Hospital Medical Center

Inventors

• Wells James M
• Spence Jason R
• Zorn Aaron M
• Shroyer Noah F

Classifications

• C12N2501/155

  Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor · CPC title

• C12N2502/02

  embryonic cells · CPC title

• C12N2501/415

  Wnt; Frizzeled · CPC title

• C12N2501/16

  Activin; Inhibin; Mullerian inhibiting substance · CPC title

• C12N5/0661

  Smooth muscle cells · CPC title